Beyond empiricism: Informing vaccine development through innate immunity research

Cell

Volumn 148, Issue 6, 2012, Pages 1284-1292

  Levitz, Stuart M ^a   Golenbock, Douglas T ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DENDRITIC CELL VACCINE; FLAGELLIN; IMIQUIMOD; INFLUENZA VACCINE; LIVE VACCINE; RESIQUIMOD; VACCINE;

ADAPTIVE IMMUNITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; INFECTION; INFLUENZA; INNATE IMMUNITY; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKIN DISEASE; TUBERCULOSIS;

EID: 84858419788     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2012.02.012     Document Type: Review

References (91)

1. A. Abbott Lyme disease: uphill struggle Nature 439 2006 524 525
2. S.S. Ahmed, S.A. Plotkin, S. Black, and R.L. Coffman Assessing the safety of adjuvanted vaccines Sci. Transl. Med. 3 2011 93rv92
3. S. Akira, S. Uematsu, and O. Takeuchi Pathogen recognition and innate immunity Cell 124 2006 783 801
4. L. Alexopoulou, V. Thomas, M. Schnare, Y. Lobet, J. Anguita, R.T. Schoen, R. Medzhitov, E. Fikrig, and R.A. Flavell Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice Nat. Med. 8 2002 878 884
5. K.P. Asante, S. Abdulla, S. Agnandji, J. Lyimo, J. Vekemans, S. Soulanoudjingar, R. Owusu, M. Shomari, A. Leach, and E. Jongert Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial Lancet Infect. Dis. 11 2011 741 749
6. M. Barry, and C. Cooper Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy Expert Opin. Biol. Ther. 7 2007 1731 1737
7. J.M. Blander, and R. Medzhitov Toll-dependent selection of microbial antigens for presentation by dendritic cells Nature 440 2006 808 812
8. L.C. Bonifaz, D.P. Bonnyay, A. Charalambous, D.I. Darguste, S. Fujii, H. Soares, M.K. Brimnes, B. Moltedo, T.M. Moran, and R.M. Steinman In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination J. Exp. Med. 199 2004 815 824
9. C.F. Brereton, and J.M. Blander The unexpected link between infection-induced apoptosis and a TH17 immune response J. Leukoc. Biol. 89 2011 565 576
10. H.D. Brightbill, D.H. Libraty, S.R. Krutzik, R.-B. Yang, J.T. Belisle, J.R. Bleharski, M. Maitland, M.V. Norgard, S.E. Plevy, and S.T. Smale Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors Science 285 1999 732 736
11. M.M. Brinkmann, E. Spooner, K. Hoebe, B. Beutler, H.L. Ploegh, and Y.-M. Kim The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling J. Cell Biol. 177 2007 265 275
12. C.L. Bueter, C.K. Lee, V.A. Rathinam, G.J. Healy, C.H. Taron, C.A. Specht, and S.M. Levitz Chitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis J. Biol. Chem. 286 2011 35447 35455
13. D.L. Burdette, K.M. Monroe, K. Sotelo-Troha, J.S. Iwig, B. Eckert, M. Hyodo, Y. Hayakawa, and R.E. Vance STING is a direct innate immune sensor of cyclic di-GMP Nature 478 2011 515 518
14. J.M. Burke, L.M. Ganley-Leal, A. Khatri, and L.M. Wetzler Neisseria meningitidis PorB, a TLR2 ligand, induces an antigen-specific eosinophil recall response: potential adjuvant for helminth vaccines? J. Immunol. 179 2007 3222 3230
15. C.R. Casella, and T.C. Mitchell Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant Cell. Mol. Life Sci. 65 2008 3231 3240
16. W. Chen, R. Kuolee, and H. Yan The potential of 3′,5′-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant Vaccine 28 2010 3080 3085
17. T. Clapp, P. Siebert, D. Chen, and L. Jones Braun Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability J. Pharm. Sci. 100 2011 388 401
18. R.L. Coffman, A. Sher, and R.A. Seder Vaccine adjuvants: putting innate immunity to work Immunity 33 2010 492 503
19. R.N. Coler, S. Bertholet, M. Moutaftsi, J.A. Guderian, H.P. Windish, S.L. Baldwin, E.M. Laughlin, M.S. Duthie, C.B. Fox, and D. Carter Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant PLoS ONE 6 2011 e16333
20. S.L. Demento, A.L. Siefert, A. Bandyopadhyay, F.A. Sharp, and T.M. Fahmy Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines Trends Biotechnol. 29 2011 294 306
21. A.M. Didierlaurent, S. Morel, L. Lockman, S.L. Giannini, M. Bisteau, H. Carlsen, A. Kielland, O. Vosters, N. Vanderheyde, and F. Schiavetti AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity J. Immunol. 183 2009 6186 6197
22. P. Duewell, U. Kisser, K. Heckelsmiller, S. Hoves, P. Stoitzner, S. Koernig, A.B. Morelli, B.E. Clausen, M. Dauer, and A. Eigler ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells J. Immunol. 187 2011 55 63
23. M. Dupuis, T.J. Murphy, D. Higgins, M. Ugozzoli, G. van Nest, G. Ott, and D.M. McDonald Dendritic cells internalize vaccine adjuvant after intramuscular injection Cell. Immunol. 186 1998 18 27
24. S.C. Eisenbarth, O.R. Colegio, W. O'Connor, F.S. Sutterwala, and R.A. Flavell Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants Nature 453 2008 1122 1126
25. P. Eitz Ferrer, S. Potthoff, S. Kirschnek, G. Gasteiger, W. Kastenmüller, H. Ludwig, S.A. Paschen, A. Villunger, G. Sutter, I. Drexler, and G. Häcker Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-β-dependent induction of pro-apoptotic Noxa PLoS Pathog. 7 2011 e1002083
26. E. Elinav, T. Strowig, J. Henao-Mejia, and R.A. Flavell Regulation of the antimicrobial response by NLR proteins Immunity 34 2011 665 679
27. T.L. Flach, G. Ng, A. Hari, M.D. Desrosiers, P. Zhang, S.M. Ward, M.E. Seamone, A. Vilaysane, A.D. Mucsi, and Y. Fong Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity Nat. Med. 17 2011 479 487
28. L. Franchi, and G. Núñez The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity Eur. J. Immunol. 38 2008 2085 2089
29. N. Garon, L. Segal, F. Tavares, and M. Van Mechelen The safety evaluation of adjuvants during vaccine development: the AS04 experience Vaccine 29 2011 4453 4459
30. A.L. Gavin, K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, and D. Nemazee Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling Science 314 2006 1936 1938
31. S.L. Giannini, E. Hanon, P. Moris, M. Van Mechelen, S. Morel, F. Dessy, M.A. Fourneau, B. Colau, J. Suzich, and G. Losonksy Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only Vaccine 24 2006 5937 5949
32. A.T. Glenny, C.G. Pope, H. Waddington, and U. Wallace Immunological notes. XVII-XXIV J. Pathol. Bacteriol. 29 1926 31 40
33. U. Gowthaman, V. Singh, W. Zeng, S. Jain, K.F. Siddiqui, S.B. Chodisetti, R.K. Gurram, P. Parihar, P. Gupta, and U.D. Gupta Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T-cell response J. Infect. Dis. 204 2011 1328 1338
34. M. Gunzer, H. Riemann, Y. Basoglu, A. Hillmer, C. Weishaupt, S. Balkow, B. Benninghoff, B. Ernst, M. Steinert, and T. Scholzen Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion Blood 106 2005 2424 2432
35. G. Hajishengallis, and J.D. Lambris Microbial manipulation of receptor crosstalk in innate immunity Nat. Rev. Immunol. 11 2011 187 200
36. B. He, R. Santamaria, W. Xu, M. Cols, K. Chen, I. Puga, M. Shan, H. Xiong, J.B. Bussel, and A. Chiu The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88 Nat. Immunol. 11 2010 836 845
37. J. Hinchey, B.Y. Jeon, H. Alley, B. Chen, M. Goldberg, S. Derrick, S. Morris, W.R. Jacobs Jr., S.A. Porcelli, and S. Lee Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis PLoS ONE 6 2011 e15857
38. V. Hornung, A. Ablasser, M. Charrel-Dennis, F. Bauernfeind, G. Horvath, D.R. Caffrey, E. Latz, and K.A. Fitzgerald AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC Nature 458 2009 514 518
39. V. Hornung, F. Bauernfeind, A. Halle, E.O. Samstad, H. Kono, K.L. Rock, K.A. Fitzgerald, and E. Latz Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization Nat. Immunol. 9 2008 847 856
40. V. Hornung, and E. Latz Intracellular DNA recognition Nat. Rev. Immunol. 10 2010 123 130
41. H. Huang, G.R. Ostroff, C.K. Lee, C.A. Specht, and S.M. Levitz Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles MBio. 1 2010 e00164-e00110
42. T. Ichinohe, S.-i. Tamura, A. Kawaguchi, A. Ninomiya, M. Imai, S. Itamura, T. Odagiri, M. Tashiro, H. Takahashi, and H. Sawa Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine J. Infect. Dis. 196 2007 1313 1320
43. K.J. Ishii, T. Kawagoe, S. Koyama, K. Matsui, H. Kumar, T. Kawai, S. Uematsu, O. Takeuchi, F. Takeshita, C. Coban, and S. Akira TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines Nature 451 2008 725 729
44. A.S. Jegede What led to the Nigerian boycott of the polio vaccination campaign? PLoS Med. 4 2007 e73
45. M.B. Jordan, D.M. Mills, J. Kappler, P. Marrack, and J.C. Cambier Promotion of B cell immune responses via an alum-induced myeloid cell population Science 304 2004 1808 1810
46. P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, D.F. Penson, C.H. Redfern, A.C. Ferrari, R. Dreicer, R.B. Sims IMPACT Study Investigators Sipuleucel-T immunotherapy for castration-resistant prostate cancer N. Engl. J. Med. 363 2010 411 422
47. S.P. Kasturi, I. Skountzou, R.A. Albrecht, D. Koutsonanos, T. Hua, H.I. Nakaya, R. Ravindran, S. Stewart, M. Alam, and M. Kwissa Programming the magnitude and persistence of antibody responses with innate immunity Nature 470 2011 543 547
48. S.H.E. Kaufmann Future vaccination strategies against tuberculosis: thinking outside the box Immunity 33 2010 567 577
49. Q. Kong, D.A. Six, K.L. Roland, Q. Liu, L. Gu, C.M. Reynolds, X. Wang, C.R.H. Raetz, and R. Curtiss 3rd Salmonella synthesizing 1-dephosphorylated lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity J. Immunol. 187 2011 412 423
50. M. Kool, V. Pétrilli, T. De Smedt, A. Rolaz, H. Hammad, M. van Nimwegen, I.M. Bergen, R. Castillo, B.N. Lambrecht, and J. Tschopp Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome J. Immunol. 181 2008 3755 3759
51. M. Kool, M.A. Willart, M. van Nimwegen, I. Bergen, P. Pouliot, J.C. Virchow, N. Rogers, F. Osorio, C. Reis E Sousa, H. Hammad, and B.N. Lambrecht An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma Immunity 34 2011 527 540
52. E. Kuroda, K.J. Ishii, S. Uematsu, K. Ohata, C. Coban, S. Akira, K. Aritake, Y. Urade, and Y. Morimoto Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome- independent mechanisms Immunity 34 2011 514 526
53. J.S. Lam, M.K. Mansour, C.A. Specht, and S.M. Levitz A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity J. Immunol. 175 2005 7496 7503
54. E. Latz, A. Schoenemeyer, A. Visintin, K.A. Fitzgerald, B.G. Monks, C.F. Knetter, E. Lien, N.J. Nilsen, T. Espevik, and D.T. Golenbock TLR9 signals after translocating from the ER to CpG DNA in the lysosome Nat. Immunol. 5 2004 190 198
55. S. LeibundGut-Landmann, O. Gross, M.J. Robinson, F. Osorio, E.C. Slack, S.V. Tsoni, E. Schweighoffer, V. Tybulewicz, G.D. Brown, J. Ruland, and C. Reis e Sousa Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17 Nat. Immunol. 8 2007 630 638
56. Y.-M. Loo, and M. Gale Jr. Immune signaling by RIG-I-like receptors Immunity 34 2011 680 692
57. J.M. Luke, G.G. Simon, J. Söderholm, J.S. Errett, J.T. August, M. Gale Jr., C.P. Hodgson, and J.A. Williams Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine J. Virol. 85 2011 1370 1383
58. J.W. Mannhalter, H.O. Neychev, G.J. Zlabinger, R. Ahmad, and M.M. Eibl Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation Clin. Exp. Immunol. 61 1985 143 151
59. T. Marichal, K. Ohata, D. Bedoret, C. Mesnil, C. Sabatel, K. Kobiyama, P. Lekeux, C. Coban, S. Akira, and K.J. Ishii DNA released from dying host cells mediates aluminum adjuvant activity Nat. Med. 17 2011 996 1002
60. P. Marrack, A.S. McKee, and M.W. Munks Towards an understanding of the adjuvant action of aluminium Nat. Rev. Immunol. 9 2009 287 293
61. V. Mata-Haro, C. Cekic, M. Martin, P.M. Chilton, C.R. Casella, and T.C. Mitchell The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4 Science 316 2007 1628 1632
62. M.L. Mbow, E. De Gregorio, N.M. Valiante, and R. Rappuoli New adjuvants for human vaccines Curr. Opin. Immunol. 22 2010 411 416
63. A.S. McKee, M.W. Munks, and P. Marrack How do adjuvants work? Important considerations for new generation adjuvants Immunity 27 2007 687 690
64. S.B. Mizel, and J.T. Bates Flagellin as an adjuvant: cellular mechanisms and potential J. Immunol. 185 2010 5677 5682
65. S. Morel, A. Didierlaurent, P. Bourguignon, S. Delhaye, B. Baras, V. Jacob, C. Planty, A. Elouahabi, P. Harvengt, and H. Carlsen Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity Vaccine 29 2011 2461 2473
66. F. Mosca, E. Tritto, A. Muzzi, E. Monaci, F. Bagnoli, C. Iavarone, D. O'Hagan, R. Rappuoli, and E. De Gregorio Molecular and cellular signatures of human vaccine adjuvants Proc. Natl. Acad. Sci. USA 105 2008 10501 10506
67. L.A. O'Neill, and A.G. Bowie Sensing and signaling in antiviral innate immunity Curr. Biol. 20 2010 R328 R333
68. F. Osorio, and C. Reis e Sousa Myeloid C-type lectin receptors in pathogen recognition and host defense Immunity 34 2011 651 664
69. I.G. Ovsyannikova, I.H. Haralambieva, N. Dhiman, M.M. O'Byrne, V.S. Pankratz, R.M. Jacobson, and G.A. Poland Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination J. Infect. Dis. 201 2010 207 213
70. M. Pellegrini, U. Nicolay, K. Lindert, N. Groth, and G. Della Cioppa MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database Vaccine 27 2009 6959 6965
71. B. Pulendran, and R. Ahmed Immunological mechanisms of vaccination Nat. Immunol. 12 2011 509 517
72. T. Querec, S. Bennouna, S. Alkan, Y. Laouar, K. Gorden, R. Flavell, S. Akira, R. Ahmed, and B. Pulendran Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity J. Exp. Med. 203 2006 413 424
73. T.D. Querec, R.S. Akondy, E.K. Lee, W. Cao, H.I. Nakaya, D. Teuwen, A. Pirani, K. Gernert, J. Deng, and B. Marzolf Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans Nat. Immunol. 10 2009 116 125
74. D. Rajagopal, C. Paturel, Y. Morel, S. Uematsu, S. Akira, and S.S. Diebold Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists Blood 115 2010 1949 1957
75. R. Rappuoli, C.W. Mandl, S. Black, and E. De Gregorio Vaccines for the twenty-first century society Nat. Rev. Immunol. 11 2011 865 872
76. M. Scarselli, B. Aric, B. Brunelli, S. Savino, F. Di Marcello, E. Palumbo, D. Veggi, L. Ciucchi, E. Cartocci, and M.J. Bottomley Rational design of a meningococcal antigen inducing broad protective immunity Sci. Transl. Med. 3 2011 91ra62
77. H. Schoenen, B. Bodendorfer, K. Hitchens, S. Manzanero, K. Werninghaus, F. Nimmerjahn, E.M. Agger, S. Stenger, P. Andersen, and J. Ruland Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate J. Immunol. 184 2010 2756 2760
78. A. Sette, and R. Rappuoli Reverse vaccinology: developing vaccines in the era of genomics Immunity 33 2010 530 541
79. A. Seubert, S. Calabro, L. Santini, B. Galli, A. Genovese, S. Valentini, S. Aprea, A. Colaprico, U. D'Oro, and M.M. Giuliani Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88 Proc. Natl. Acad. Sci. USA 108 2011 11169 11174
80. F. Shann The nonspecific effects of vaccines and the expanded program on immunization J. Infect. Dis. 204 2011 182 184
81. S. Sharma, R.B. DeOliveira, P. Kalantari, P. Parroche, N. Goutagny, Z. Jiang, J. Chan, D.C. Bartholomeu, F. Lauw, and J.P. Hall Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome Immunity 35 2011 194 207
82. X.T. Song, K. Evel-Kabler, L. Rollins, M. Aldrich, F. Gao, X.F. Huang, and S.Y. Chen An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells PLoS Med. 3 2006 e11
83. X.T. Song, K. Evel-Kabler, L. Shen, L. Rollins, X.F. Huang, and S.Y. Chen A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression Nat. Med. 14 2008 258 265
84. A.C. Stubbs, K.S. Martin, C. Coeshott, S.V. Skaates, D.R. Kuritzkes, D. Bellgrau, A. Franzusoff, R.C. Duke, and C.C. Wilson Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity Nat. Med. 7 2001 625 629
85. P.J. Tacken, and C.G. Figdor Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines Semin. Immunol. 23 2011 12 20
86. D.N. Taylor, J.J. Treanor, C. Strout, C. Johnson, T. Fitzgerald, U. Kavita, K. Ozer, L. Tussey, and A. Shaw Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI) Vaccine 29 2011 4897 4902
87. The RTS, S Clinical Trials Partnership First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children N. Engl. J. Med. 365 2011 1863 1875
88. S.E. Warren, H. Duong, D.P. Mao, A. Armstrong, J. Rajan, E.A. Miao, and A. Aderem Generation of a Listeria vaccine strain by enhanced caspase-1 activation Eur. J. Immunol. 41 2011 1934 1940
89. M. Wuthrich, H.I. Filutowicz, T. Warner, G.S. Deepe Jr., and B.S. Klein Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts J. Exp. Med. 197 2003 1405 1416
90. Y. Zhao, J. Yang, J. Shi, Y.-N. Gong, Q. Lu, H. Xu, L. Liu, and F. Shao The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus Nature 477 2011 596 600
91. Q. Zhu, C. Egelston, A. Vivekanandhan, S. Uematsu, S. Akira, D.M. Klinman, I.M. Belyakov, and J.A. Berzofsky Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines Proc. Natl. Acad. Sci. USA 105 2008 16260 16265